Albendazole in human loiasis: results of a double-blind, placebo-controlled trial.

@article{Klion1993AlbendazoleIH,
  title={Albendazole in human loiasis: results of a double-blind, placebo-controlled trial.},
  author={Amy D Klion and Achille Massougbodji and John Horton and S Ekou{\'e} and T Lanmasso and N L Ahouissou and Thomas B Nutman},
  journal={The Journal of infectious diseases},
  year={1993},
  volume={168 1},
  pages={202-6}
}
To assess the filaricidal activity and clinical safety of albendazole in human loiasis, a double-blind, placebo-controlled study was conducted in an endemic area in Benin, Africa. Twenty-three men with microfilaremia (100-30,000/mL) were randomly assigned to receive albendazole (200 mg; n = 11) or placebo (n = 12) twice daily for 21 days; 1 patient from each group withdrew from the study. There were no clinical adverse effects and no observed hepatotoxicity, renal toxicity, or hematologic… CONTINUE READING